ClinicalTrials.Veeva

Menu
K

Klinika Reuma Park Sp. z o.o. sp. k. | Centrum Medyczne Reuma Park

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lutikizumab
JNJ-77242113
ABT-494
Guselkumab
ESK-001
Upadacitinib
Zasocitinib
JNJ-88545223
Paracetamol
Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 23 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Dise...

Active, not recruiting
Primary Sjogrens Disease
Biological: Efgartigimod PH20 SC
Other: Placebo PH20 SC

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling
Psoriatic Arthritis
Drug: Active Comparator
Drug: Zasocitinib

This study will assess the efficacy and safety of Afimkibart (also known as RO7790121) compared with placebo in participants with moderate to severe...

Enrolling
Rheumatoid Arthritis
Drug: Placebo
Drug: Afimkibart

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will evaluate th...

Enrolling
Rheumatoid Arthritis
Drug: Lutikizumab
Drug: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 i...

Active, not recruiting
Colitis, Ulcerative
Inflammatory Bowel Diseases
Drug: MORF-057
Drug: Placebo

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic a...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Icotrokinra

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by ass...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Active reference comparator

The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with ac...

Enrolling
Arthritis, Psoriatic
Drug: JNJ-88545223
Drug: Placebo

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

This phase 2a trial is an international, multicenter, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of on...

Enrolling
Synovitis of Knee
Knee Osteoarthritis
Drug: 4P004
Drug: Placebo (NaCl 0.9%)

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Active, not recruiting
Rheumatoid Arthritis
Drug: LY3871801
Drug: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Active, not recruiting
Psoriasis
Severe Psoriasis
Drug: Open-Label Envudeucitinib
Drug: Blinded Envudeucitinib

This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacod...

Enrolling
Rheumatoid Arthritis
Other: Placebo
Drug: LFD-200

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, sti...

Enrolling
Psoriatic Arthritis
Drug: Risankizumab
Drug: Lutikizumab

Trial sponsors

Janssen (J&J Innovative Medicine) logo
AbbVie logo
A
Lilly logo
argenx logo
4
Angelini Pharma logo
Bristol-Myers Squibb (BMS) logo
Roche logo
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems